Viridian Therapeutics, Inc. · NASDAQ:VRDN

Viridian Therapeutics — Technical Presentation (March 2026)

20 slides from Viridian Therapeutics's technical presentation, Mar 30, 2026

  1. Slide 1: Elegrobart REVEAL-1 Topline Results

    Elegrobart REVEAL-1 Topline Results March 30, 2026

  2. Slide 2: Cautionary note regarding forward-looking statements

    Cautionary note regarding forward-looking statements Cautionary note regarding forward-looking statements This presentation and the related teleconference contain forward-looking statements. These statements may be identified by the use of words such as, but not limited to, “anticipate,” “believe,”

  3. Slide 3: Agenda

    Agenda Steve Mahoney Introduction President & Chief Executive Officer Radhika Tripuraneni, MD REVEAL-1 Phase 3 Topline Results Chief Medical Officer Steve Mahoney Closing Remarks President & Chief Executive Officer Steve Mahoney, President & Chief Executive Officer Radhika Tripuraneni, MD, Chief Med

  4. Slide 4: Viridian is developing an IGF-1R antibody franchise with the potential to transform the treatment of patients with TED

    Viridian is developing an IGF-1R antibody franchise with the potential to transform the treatment of patients with TED Topline data today Elegrobart Veligrotug Teprotumumab Potential to be the first subcutaneous autoinjector in TED Steroids/Surgery Next-gen anti-IGF-1R with potential to Q4W or Q8W F

  5. Slide 5: REVEAL-1 in active TED patients met primary endpoint and elegrobart was generally well tolerated

    REVEAL-1 in active TED patients met primary endpoint and elegrobart was generally well tolerated Achieved the primary endpoint with high statistical significance (p < 0.0001); 54% of Q4W patients achieved a proptosis response versus 18% placebo at week 24 Achieved clinically meaningful outcomes on m

  6. Slide 6: REVEAL-1 is a phase 3 randomized, controlled, double-masked trial of elegrobart in active TED

    REVEAL-1 is a phase 3 randomized, controlled, double-masked trial of elegrobart in active TED Treatment Phase (20 weeks treatment with primary endpoint at 24 weeks) Treatment Arms D11 W4 W8 W12 W16 W20 W24 Follow-up (1:1:1) through W52 Primary Endpoint Elegrobart Q4W1 Analysis Primary efficacy endpo

  7. Slide 7: REVEAL-1 is the largest pivotal clinical trial conducted in active TED to date

    REVEAL-1 is the largest pivotal clinical trial conducted in active TED to date Randomized Patients (n = 132) Elegrobart Q4W Elegrobart Q8W Placebo (n = 44) (n = 44) (n = 44) Discontinued • 1 TEAE (Gr1 amylase / lipase elevation) Discontinued Discontinued • 2 withdrawal of consent • 2 withdrawal of c

  8. Slide 8: REVEAL-1 baseline characteristics were well-balanced between arms

    REVEAL-1 baseline characteristics were well-balanced between arms 7.8 Elegrobart Q4W Elegrobart Q8W Placebo (n = 44) (n = 44) (n = 44) Age in years, mean (SD) 52.6 (12.1) 48.1 (12.4) 48.5 (12.9) Participant Female sex, n (%) 35 (80%) 34 (77%) 35 (80%) Demographics White race, n (%) 36 (82%) 36 (82%)

  9. Slide 9: REVEAL-1 achieved high statistical significance on primary endpoint at 24 weeks

    REVEAL-1 achieved high statistical significance on primary endpoint at 24 weeks Elegrobart Placebo p-value (n = 44 per arm) (n = 44) Primary FDA: Proptosis responder rate (exophthalmometry)1 54% 18% p < 0.0001* Q4W Endpoint EMA: Overall responder rate (ORR)2 51% 16% p = 0.0001* Proptosis mean change

  10. Slide 10: Significant proptosis responder rate as early as 4 weeks after just one dose and across all time points

    Significant proptosis responder rate as early as 4 weeks after just one dose and across all time points in both arms Proptosis Responder Rate – Q4W Proptosis Responder Rate – Q8W 100 Primary 100 endpoint: Proptosis Responder Rate (%) Proptosis Responder Rate (%) p < 0.0001 80 80 62% 63% 62% 63% 54%

  11. Slide 11: Significant proptosis mean change from baseline at all time points across both treatment arms

    Significant proptosis mean change from baseline at all time points across both treatment arms, including at week 4 Mean Change from Baseline – Q4W Mean Change from Baseline – Q8W -0.21 -0.30 Key secondary -0.21 -0.30 0 endpoint: 0 -0.52 -0.49 p < 0.0001 -0.52 -0.49 Proptosis Mean Reduction (mm) Prop

  12. Slide 12: Proptosis endpoints as measured by MRI were consistent with exophthalmometer

    Proptosis endpoints as measured by MRI were consistent with exophthalmometer, and significant at all time points Proptosis Responder Rate (MRI) Proptosis Mean Change from Baseline (MRI) -0.13 -0.22 100 0 90 Proptosis Mean Reduction (mm) 80 Proptosis Responder Rate (%) 70 -1 60 50% 43% -1.69 50 -1.99

  13. Slide 13: Diplopia responder rate and complete resolution for elegrobart Q4W improved throughout treatment period

    Diplopia responder rate and complete resolution for patients receiving elegrobart Q4W improved throughout treatment period Diplopia Responder Rate – Q4W Diplopia Complete Resolution – Q4W 100 100 74% 71% 80 80 Diplopia Responder Rate (%) Diplopia Resolution Rate (%) 58% 54% 52% 50% 50% 60 60 43% 33%

  14. Slide 14: Elegrobart was generally well tolerated through week 24

    Elegrobart was generally well tolerated through week 24 Elegrobart Q4W Elegrobart Q8W Placebo N=44 N=44 N=44 n (%) n (%) n (%) Participants with any treatment-emergent 40 (91%) 31 (70%) 24 (55%) adverse event (TEAE) Participants with any serious AE (SAE) 2 (5%)1 2 (5%)2 0 Participants with any treat

  15. Slide 15: AE categories for elegrobart in REVEAL-1 were consistent with those expected from the anti-IGF-1R class

    AE categories for elegrobart in REVEAL-1 were consistent with those generally expected from the anti-IGF-1R class Elegrobart Q4W Elegrobart Q8W Placebo AEs occurring at ≥10% frequency in any arm N=44 N=44 N=44 n (%) n (%) n (%) Muscle spasms 18 (41%) 16 (36%) 3 (7%) Injection site reactions (ISR)1,2

  16. Slide 16: REVEAL-1 in active TED patients met primary endpoint and elegrobart was generally well tolerated

    REVEAL-1 in active TED patients met primary endpoint and elegrobart was generally well tolerated Achieved the primary endpoint with high statistical significance (p < 0.0001); 54% of Q4W patients achieved a proptosis response versus 18% placebo at week 24 Achieved clinically meaningful outcomes on m

  17. Slide 17: REVEAL-2 in chronic TED is on track for topline data readout in Q2 2026

    REVEAL-2 in chronic TED, the second pivotal phase 3 study for elegrobart, is on track for topline data readout in Q2 2026 CHRONIC TED Key Inclusion Criteria Trial Design • Proptosis of ≥3 mm • N = 195 (actual enrollment: 204 • Any CAS (0–7) patients) • Onset of TED symptoms • 24-week primary endpoin

  18. Slide 18: Veligrotug: Approaching full launch-readiness in preparation for June 30 PDUFA target action date

    Veligrotug: Approaching full launch-readiness in preparation for June 30 PDUFA target action date under Priority Review Veligrotug is well positioned to become the Launch preparations well underway with IV treatment-of-choice for TED patients1,2 experienced team in place Diplopia Resolution & Respon

  19. Slide 19: Viridian has the potential to provide multiple differentiated treatment solutions for TED patients in one portfolio

    Viridian has the potential to provide multiple differentiated treatment solutions for TED patients in one portfolio TED Future: Next-Gen Anti-IGF-1R TED Present TED Past Veligrotug2 Elegrobart2 Potential to become the Potential to be IV treatment of choice the first subcutaneous Teprotumumab1 in TED

  20. Slide 20: Thank you to the TED community

    Thank you to the TED community: patients, advocates, investigators, research staff, and partners who made this trial a success 20

Viridian Therapeutics — Technical Presentation (March 2026) on 6ix